S. Evans

发表

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

John Seibyl, Mark Stacy, Stanley Fahn, 2004, Archives of neurology.

Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia

S. Factor, E. Molho, P. Feustel, 2005, Movement disorders : official journal of the Movement Disorder Society.

Long-Term Comparative Experience with Tolcapone and Entacapone in Advanced Parkinson's Disease

S. Factor, E. Molho, P. Feustel, 2001, Clinical neuropharmacology.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Stephanie D. Wilson, S. Ellias, J. Nutt, 2014, JAMA neurology.

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

Jane S. Paulsen, J. Jankovic, T. Brashers-Krug, 2016, JAMA.

The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study

J. Jankovic, P. Tariot, B. Leavitt, 2022, CNS Drugs.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

Jane S. Paulsen, Megan M. Romer, J. Jankovic, 2016, JAMA neurology.

Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families.

J. Jankovic, K. Marder, W. Weiner, 2003, Human molecular genetics.

Significant linkage of Parkinson disease to chromosome 2q36-37.

L. Seeberger, E. Siemers, K. Marder, 2003, American journal of human genetics.

Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease

L. Seeberger, K. Marder, D. Jennings, 2003, Neurology.